Callan Family Office LLC Raises Stock Holdings in Novartis AG (NYSE:NVS)

Callan Family Office LLC lifted its holdings in shares of Novartis AG (NYSE:NVS - Free Report) by 1,418.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,874 shares of the company's stock after buying an additional 26,973 shares during the quarter. Callan Family Office LLC's holdings in Novartis were worth $2,810,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of NVS. Centaurus Financial Inc. lifted its position in shares of Novartis by 1.7% during the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock worth $659,000 after acquiring an additional 98 shares in the last quarter. WealthPlan Investment Management LLC lifted its holdings in Novartis by 1.1% during the 3rd quarter. WealthPlan Investment Management LLC now owns 9,494 shares of the company's stock worth $1,092,000 after purchasing an additional 100 shares in the last quarter. Bryn Mawr Capital Management LLC lifted its holdings in Novartis by 0.8% during the 4th quarter. Bryn Mawr Capital Management LLC now owns 12,884 shares of the company's stock worth $1,254,000 after purchasing an additional 100 shares in the last quarter. Rothschild Investment LLC boosted its stake in Novartis by 0.6% in the 4th quarter. Rothschild Investment LLC now owns 16,682 shares of the company's stock worth $1,623,000 after purchasing an additional 101 shares during the period. Finally, Avidian Wealth Enterprises LLC grew its holdings in Novartis by 1.3% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 7,913 shares of the company's stock valued at $910,000 after buying an additional 102 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Novartis Stock Down 3.5 %

Shares of Novartis stock traded down $3.99 during midday trading on Tuesday, hitting $111.48. The company had a trading volume of 2,021,182 shares, compared to its average volume of 2,066,343. The company has a 50 day moving average of $104.38 and a 200 day moving average of $107.87. The stock has a market capitalization of $227.87 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.70 and a beta of 0.53. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.84 and a current ratio of 1.04.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Friday, January 31st. The company reported $1.98 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.18. Novartis had a return on equity of 37.24% and a net margin of 23.56%. On average, equities analysts predict that Novartis AG will post 8.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on NVS. HSBC downgraded shares of Novartis from a "hold" rating to a "reduce" rating in a report on Wednesday, December 4th. Barclays reaffirmed an "underweight" rating on shares of Novartis in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft raised shares of Novartis from a "hold" rating to a "buy" rating in a report on Tuesday, February 4th. Erste Group Bank reaffirmed a "hold" rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, Morgan Stanley began coverage on Novartis in a report on Wednesday, February 12th. They issued an "underweight" rating for the company. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Novartis currently has an average rating of "Hold" and a consensus target price of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.